Report: Jacoby Ellsbury out at least six weeks with shoulder dislocation

28 Comments

UPDATE: Gordon Edes of ESPNBoston.com reports that Ellsbury does indeed have a dislocation or partial dislocation of his right shoulder and will miss a minimum of six weeks. He is scheduled to undergo more testing to make sure the shoulder did not sustain additional damage.

10:04 PM: Alex Speier of WEEI.com was told by an “industry source with knowledge of the situation” that Ellsbury likely suffered a dislocation or subluxation of his right shoulder.

The Red Sox have yet to make an official announcement on his status, but if Speier’s report proves correct, Ellsbury could miss up to six to eight weeks. There’s also the possibility that he could need season-ending surgery if the shoulder fails to respond to rest and rehabilitation.

8:49 PM: According to Scott Lauber of the Boston Herald, Jacoby Ellsbury was sent to Massachusetts General Hospital in order to undergo tests, including an MRI exam, on his right shoulder. Ellsbury left this afternoon’s game against the Rays in the bottom of the fourth inning after sliding into second base and having Reid Brignac fall directly on top of him.

The full extent of the injury isn’t yet known, but the Red Sox are already preparing for life without him. At least for a little while. Red Sox manager Bobby Valentine said the club is planning to make a roster move and Triple-A Pawtucket radio announcer Aaron Goldsmith notes that prospect outfielder Che-Hsuan Lin was scratched from tonight’s lineup. Seems like he’ll get the call.

In the interim, the Red Sox will likely start Darnell McDonald, Cody Ross and Ryan Sweeney from left to right in the outfield while Mike Aviles figures to slide into the leadoff spot. Be afraid, American League hurlers.

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
1 Comment

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.